Migraine affects 5-6% of children and 10-15% of teenagers and adolescents. Research efforts over the past decade have resulted in several FDA-approved treatments, of which the CGRP antibodies are the most impactful. Unfortunately, many of these treatments will remain unavailable to children and teenagers until studies are performed to demonstrate benefit and safety similar to that observed in adults.
In collaboration with our research sponsor company partners, MedVadis is working to change this. If your child suffers from migraine, please consider participating in one of our pediatric migraine trials. Together we can improve the lives of every child who suffers from this debilitating condition.
Healthcare insurance is not required and you may be reimbursed for your time.